TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurosense Therapeutics Ltd. ( (NRSN) ) has provided an announcement.
NeuroSense Therapeutics Ltd. recently released an analysis of 18-month data from its Phase 2b PARADIGM study, which evaluated the efficacy of PrimeC in treating ALS. The study demonstrated a statistically significant effect, with a 28% relative difference in ALS Functional Rating Scale-Revised decline favoring patients who received PrimeC early. This underscores the importance of early treatment initiation and reinforces PrimeC’s potential as a disease-modifying therapy for ALS.
The most recent analyst rating on (NRSN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases. Their primary product, PrimeC, is aimed at treating Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.
Average Trading Volume: 360,227
Technical Sentiment Signal: Sell
Current Market Cap: $26.08M
For detailed information about NRSN stock, go to TipRanks’ Stock Analysis page.